Year-end is a busy time, with mounting pressure to prepare for end-of-year reviews and renewal proposals, acquire validated data for early 2026 conference abstract deadlines, and ensure budget is accounted for. If you still need to run an assay or study in 2025, now is a great time to get in touch with us.
Please provide details about your requirement and therapeutic / disease area to help us respond to you with the right information, as quickly as possible.
Our capabilities include:
Discovery services including complex small molecule hit discovery (fragments, covalent screening, and DEL), structural biology, protein sciences, target validation, hit-to-lead, lead optimization, in vitro biology, and DMPK.
Preclinical and translational research covering in vivo pharmacology for Oncology, Inflammation and Infectious disease, including models such as PDX, CDX, humanized, syngeneic, orthotopic, endometriosis, dermatology, fibrosis, GvHD, BSL2 and BSLG3 pathogens, and more.
Supporting expertise in imaging, toxicology, translational biology, microbiome, and IND-enabling studies.
